These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32122345)

  • 1. Comparison of
    Gauthé M; Zarca K; Aveline C; Lecouvet F; Balogova S; Cussenot O; Talbot JN; Durand-Zaleski I
    BMC Med Imaging; 2020 Mar; 20(1):25. PubMed ID: 32122345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of
    Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of sodium
    Gauthé M; Aveline C; Lecouvet F; Michaud L; Rousseau C; Tassart M; Cussenot O; Talbot JN; Durand-Zaleski I
    World J Urol; 2019 Aug; 37(8):1587-1595. PubMed ID: 30382380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
    Beheshti M; Rezaee A; Geinitz H; Loidl W; Pirich C; Langsteger W
    J Nucl Med; 2016 Oct; 57(Suppl 3):55S-60S. PubMed ID: 27694173
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
    Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observer Agreement and Accuracy of
    Zacho HD; Fonager RF; Nielsen JB; Haarmark C; Hendel HW; Johansen MB; Mortensen JC; Petersen LJ
    J Nucl Med; 2020 Mar; 61(3):344-349. PubMed ID: 31481577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
    Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
    Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
    J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kanoun S; Walker P; Vrigneaud JM; Depardon E; Barbier V; Humbert O; Moulin M; Créhange G; Cormier L; Loffroy R; Brunotte F; Cochet A
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):986-994. PubMed ID: 28333020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
    Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
    Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy.
    Karahissarlian V; Sargos P; Blais E; Cazeau AL; Fontes F; Petitpierre F; Rigou G; De Vaugelade C; Mariey A; Hindié E; Thomas L
    Cancer Radiother; 2020 Jul; 24(4):323-331. PubMed ID: 32532578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.